DIAMEDICA THERAPEUTICS INC (DMAC) Fundamental Analysis & Valuation

NASDAQ:DMAC • CA25253X2077

Current stock price

6.48 USD
+0.06 (+0.93%)
At close:
6.48 USD
0 (0%)
After Hours:

This DMAC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. DMAC Profitability Analysis

1.1 Basic Checks

  • DMAC had negative earnings in the past year.
  • In the past year DMAC has reported a negative cash flow from operations.
  • In the past 5 years DMAC always reported negative net income.
  • DMAC had a negative operating cash flow in each of the past 5 years.
DMAC Yearly Net Income VS EBIT VS OCF VS FCFDMAC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • DMAC has a Return On Assets of -55.96%. This is comparable to the rest of the industry: DMAC outperforms 44.10% of its industry peers.
  • DMAC has a Return On Equity of -61.85%. This is comparable to the rest of the industry: DMAC outperforms 57.06% of its industry peers.
Industry RankSector Rank
ROA -55.96%
ROE -61.85%
ROIC N/A
ROA(3y)-42.76%
ROA(5y)-40.38%
ROE(3y)-46.99%
ROE(5y)-43.82%
ROIC(3y)N/A
ROIC(5y)N/A
DMAC Yearly ROA, ROE, ROICDMAC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400 -500

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for DMAC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DMAC Yearly Profit, Operating, Gross MarginsDMAC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. DMAC Health Analysis

2.1 Basic Checks

  • DMAC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
DMAC Yearly Shares OutstandingDMAC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
DMAC Yearly Total Debt VS Total AssetsDMAC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

2.2 Solvency

  • DMAC has an Altman-Z score of 32.43. This indicates that DMAC is financially healthy and has little risk of bankruptcy at the moment.
  • DMAC has a better Altman-Z score (32.43) than 93.23% of its industry peers.
  • DMAC has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • DMAC has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 32.43
ROIC/WACCN/A
WACCN/A
DMAC Yearly LT Debt VS Equity VS FCFDMAC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • DMAC has a Current Ratio of 10.67. This indicates that DMAC is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 10.67, DMAC belongs to the top of the industry, outperforming 82.79% of the companies in the same industry.
  • DMAC has a Quick Ratio of 10.67. This indicates that DMAC is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 10.67, DMAC belongs to the best of the industry, outperforming 82.79% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.67
Quick Ratio 10.67
DMAC Yearly Current Assets VS Current LiabilitesDMAC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. DMAC Growth Analysis

3.1 Past

  • The earnings per share for DMAC have decreased strongly by -16.67% in the last year.
EPS 1Y (TTM)-16.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.56%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • DMAC is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.14% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-10.16%
EPS Next 2Y-13.24%
EPS Next 3Y-9.05%
EPS Next 5Y9.14%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DMAC Yearly Revenue VS EstimatesDMAC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
DMAC Yearly EPS VS EstimatesDMAC Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

0

4. DMAC Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for DMAC. In the last year negative earnings were reported.
  • Also next year DMAC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DMAC Price Earnings VS Forward Price EarningsDMAC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DMAC Per share dataDMAC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

  • DMAC's earnings are expected to decrease with -9.05% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.24%
EPS Next 3Y-9.05%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. DMAC Dividend Analysis

5.1 Amount

  • No dividends for DMAC!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DMAC Fundamentals: All Metrics, Ratios and Statistics

DIAMEDICA THERAPEUTICS INC

NASDAQ:DMAC (4/2/2026, 8:19:32 PM)

After market: 6.48 0 (0%)

6.48

+0.06 (+0.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-30
Earnings (Next)05-11
Inst Owners19.79%
Inst Owner Change-7.3%
Ins Owners11.14%
Ins Owner Change1.93%
Market Cap337.48M
Revenue(TTM)N/A
Net Income(TTM)-31.93M
Analysts81.82
Price Target15.81 (143.98%)
Short Float %15.39%
Short Ratio19.86
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.48%
Min EPS beat(2)-4.17%
Max EPS beat(2)7.12%
EPS beat(4)2
Avg EPS beat(4)0.65%
Min EPS beat(4)-4.17%
Max EPS beat(4)7.12%
EPS beat(8)6
Avg EPS beat(8)5.09%
EPS beat(12)9
Avg EPS beat(12)3.21%
EPS beat(16)13
Avg EPS beat(16)10.78%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.54
P/tB 6.54
EV/EBITDA N/A
EPS(TTM)-0.7
EYN/A
EPS(NY)-0.77
Fwd EYN/A
FCF(TTM)-0.53
FCFYN/A
OCF(TTM)-0.53
OCFYN/A
SpS0
BVpS0.99
TBVpS0.99
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -55.96%
ROE -61.85%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-42.76%
ROA(5y)-40.38%
ROE(3y)-46.99%
ROE(5y)-43.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 95.35%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.67
Quick Ratio 10.67
Altman-Z 32.43
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)156.03%
Cap/Depr(5y)156.72%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.56%
EPS Next Y-10.16%
EPS Next 2Y-13.24%
EPS Next 3Y-9.05%
EPS Next 5Y9.14%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-39.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-37.98%
EBIT Next 3Y-21.87%
EBIT Next 5YN/A
FCF growth 1Y-56.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-56.83%
OCF growth 3YN/A
OCF growth 5YN/A

DIAMEDICA THERAPEUTICS INC / DMAC Fundamental Analysis FAQ

What is the ChartMill fundamental rating of DIAMEDICA THERAPEUTICS INC (DMAC) stock?

ChartMill assigns a fundamental rating of 2 / 10 to DMAC.


What is the valuation status for DMAC stock?

ChartMill assigns a valuation rating of 0 / 10 to DIAMEDICA THERAPEUTICS INC (DMAC). This can be considered as Overvalued.


How profitable is DIAMEDICA THERAPEUTICS INC (DMAC) stock?

DIAMEDICA THERAPEUTICS INC (DMAC) has a profitability rating of 1 / 10.


Can you provide the financial health for DMAC stock?

The financial health rating of DIAMEDICA THERAPEUTICS INC (DMAC) is 6 / 10.